- Home
- NNBR vs CCCC Comparison
NNBR vs CCCC Comparison
Compare NNBR & CCCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NNBR
- CCCC
- Stock Information
- Founded
- NNBR 1980
- CCCC 2015
- Country
- NNBR United States
- CCCC United States
- Employees
- NNBR N/A
- CCCC N/A
- Industry
- NNBR Industrial Machinery/Components
- CCCC Biotechnology: Pharmaceutical Preparations
- Sector
- NNBR Industrials
- CCCC Health Care
- Exchange
- NNBR Nasdaq
- CCCC Nasdaq
- Market Cap
- NNBR 106.4M
- CCCC 104.4M
- IPO Year
- NNBR 1994
- CCCC 2020
- Fundamental
- Price
- NNBR $2.18
- CCCC $2.26
- Analyst Decision
- NNBR
- CCCC Buy
- Analyst Count
- NNBR 0
- CCCC 3
- Target Price
- NNBR N/A
- CCCC $12.00
- AVG Volume (30 Days)
- NNBR 405.9K
- CCCC 2.0M
- Earning Date
- NNBR 08-06-2025
- CCCC 08-04-2025
- Dividend Yield
- NNBR N/A
- CCCC N/A
- EPS Growth
- NNBR N/A
- CCCC N/A
- EPS
- NNBR N/A
- CCCC N/A
- Revenue
- NNBR $448,780,000.00
- CCCC $39,783,000.00
- Revenue This Year
- NNBR N/A
- CCCC N/A
- Revenue Next Year
- NNBR $4.96
- CCCC N/A
- P/E Ratio
- NNBR N/A
- CCCC N/A
- Revenue Growth
- NNBR N/A
- CCCC 98.56
- 52 Week Low
- NNBR $1.58
- CCCC $1.09
- 52 Week High
- NNBR $4.67
- CCCC $7.36
- Technical
- Relative Strength Index (RSI)
- NNBR 54.23
- CCCC 60.73
- Support Level
- NNBR $1.96
- CCCC $2.15
- Resistance Level
- NNBR $2.26
- CCCC $2.53
- Average True Range (ATR)
- NNBR 0.11
- CCCC 0.28
- MACD
- NNBR 0.00
- CCCC 0.02
- Stochastic Oscillator
- NNBR 64.71
- CCCC 62.13
About NNBR NN Inc.
NN Inc is a diversified industrial company that combines engineering and production capabilities with in-depth materials science expertise to design and manufacture high-precision solutions and components. It operates in two business segments: mobile solutions and power solutions. The mobile solutions segment involves growth in the general industrial and automotive end markets. Its power solutions segment involves growth in the electrical and aerospace and defense end markets.
About CCCC C4 Therapeutics Inc.
C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patients' lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. Its degrader medicines are designed to harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes. Its pipeline is Cemsidomide, CFT1946, and CFT8919.